Fut, nem toboroz1/2. fázis
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
A legfontosabb adatok
- Ki végzi
- AstraZeneca
- Hol
- Austin, Chicago, Cincinnati, Edmond, Kansas City, Las Vegas, Lenexa, Long Beach, Miami Lakes, North Charleston, Omaha, Rolling Hills Estates, Stockbridge és West Jordan (Egyesült Államok)Mind a 14 helyszín megnézése
- Azonosító
- Állapot
- Fut, nem toboroz
- Fázis
- 1/2. fázis
- Résztvevők
- 405 fő vett részt
- Kezdés
- 2025. szept. 4.
- Várható befejezés
- 2026. dec. 29.
- A vizsgálat típusa
- Beavatkozással járó, 10 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- AZD4117
- AZD5315
- Placebo
- A regiszteradat frissítve
- 2026. október 9.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 20 feltétel megnézéseKevesebb
Ki vehet részt
- Adults, ≥ 18 years of age at the time of signing the informed consent
- Participants who are medically stable such that, according to the judgement of the Investigator, hospitalization within the study period is not anticipated and the participant appears likely to be able to remain on study through the end of protocol-specified follow-up. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months prior to enrollment
- Written informed consent and any locally required authorization (eg, HIPAA in the US) obtained from the participant prior to performing any protocol-related procedures, including screening evaluations
Ki nem vehet részt
- Previous history of myocarditis, pericarditis, Guillain-Barré syndrome or any other demyelinating condition
- Receipt of any other type of seasonal influenza vaccination from 14 days before the first dose until 28 days after the administration of the last dose of IMP
- Receipt of an mRNA vaccine within 28 days before administration of IMP
- Receipt or expected receipt of any other type of licensed or investigational vaccine within 28 days prior to Visit 1 (D1) or Visit 5 (D58)
- Receipt of immunoglobulin or blood products within 6 months prior to administration of study intervention or expected receipt during the study
- Receipt of immune-modifying drugs or immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy within 6 months prior to enrollment (or expected receipt during study), or long-term systemic corticosteroid therapy (prednisolone or equivalent at a dose of ≥ 20 mg daily for more than 2 consecutive weeks) within 6 months prior to enrollment or expected receipt during study. Topical/inhaled steroids or short-term oral steroids are permitted
- Participation in another trial, or receiving interventional Study IMP, in the preceding 90 days or expected receipt of another study intervention (or participation in another trial) during the period of study follow-up
- Individuals who have had a previous confirmed or suspected illness from influenza caused by an H5N1 or H7N9 virus
- Female participants who are pregnant, lactating, or of childbearing potential and not using a highly effective method of contraception or abstinence from at least 4 weeks prior to IMP administration and until at least 6 months after IMP administration
- History of hypersensitivity to any component of the IMP
- History of hypersensitivity to penicillin and its derivatives
- History of severe adverse reaction and/or severe allergic reaction (eg, anaphylaxis associated with a vaccine
- Known or suspected autoimmune conditions as determined by history and/or physical examination
- Acute (time-limited) or febrile (temperature ≥ 38.0 °C [100.4 °F]) illness/infection within 3 days of intended IMP administration
- Abnormal findings on screening laboratory tests
- Individuals who had household contact with and/or intimate exposure to an individual with laboratory confirmed H5N1 infection, exposure to infected household poultry/ wild birds/cattle or contaminated environments with sick and dead poultry or wild birds or cattle, within 60 days prior to enrollment
- Known or suspected congenital or acquired immunodeficiency
Helyszínek itt: Egyesült Államok
- Austin, TexasHospital not named in the registry
- Chicago, IllinoisHospital not named in the registry
- Cincinnati, OhioHospital not named in the registry
- Edmond, OklahomaHospital not named in the registry
- Kansas City, MissouriHospital not named in the registry
- Las Vegas, NevadaHospital not named in the registry
- Lenexa, KansasHospital not named in the registry
- Long Beach, CaliforniaHospital not named in the registry
- Miami Lakes, FloridaHospital not named in the registry
- North Charleston, South CarolinaHospital not named in the registry
- Omaha, NebraskaHospital not named in the registry
- Rolling Hills Estates, CaliforniaHospital not named in the registry
- Stockbridge, GeorgiaHospital not named in the registry
- West Jordan, UtahHospital not named in the registry
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to evaluate the safety and immunogenicity of two investigational vaccines, AZD4117 and AZD5315 to protect against certain strains of avian Influenza A (H5N1 and H7N9 subtypes).
A vizsgálat 10 csoportja
- Arm 1: Dosage Level 1 (DL1) of AZD4117 18 to 64 years of ageA vizsgált kezelés
Participants will receive DL1 AZD4117.
Kezelés: AZD4117
- Arm 2: Dosage Level 2 (DL2) of AZD4117 18 to 64 years of ageA vizsgált kezelés
Participants will receive DL2 AZD4117.
Kezelés: AZD4117
- Arm 3: DL1 of AZD4117 >= 65 years of ageA vizsgált kezelés
Participants will receive DL1 AZD4117.
Kezelés: AZD4117
- Arm 4: DL2 of AZD4117 >= 65 years of ageA vizsgált kezelés
Participants will receive DL2 AZD4117.
Kezelés: AZD4117
- Arm 5: DL1 of AZD5315 18 to 64 years of ageA vizsgált kezelés
Participants will receive DL1 AZD5315.
Kezelés: AZD5315
- Arm 6: DL2 of AZD5315 18 to 64 years of ageA vizsgált kezelés
Participants will receive DL2 AZD5315.
Kezelés: AZD5315
- Arm 7: DL1 of AZD5315 >= 65 years of ageA vizsgált kezelés
Participants will receive DL1 AZD5315.
Kezelés: AZD5315
- Arm 8: DL2 of AZD5315 >= 65 years of ageA vizsgált kezelés
Participants will receive DL2 AZD5315.
Kezelés: AZD5315
- Arm 9: placebo 18 to 64 years of agePlacebo, összehasonlításként
Participants will receive placebo.
Kezelés: Placebo
- Arm 10: placebo >= 65 years of agePlacebo, összehasonlításként
Participants will receive placebo.
Kezelés: Placebo
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase I/II, Double-blinded, Randomized, Placebo-Controlled, Dose Selection Study in Adults to Assess the Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
- A regiszteradat frissítve
- 2026. október 9.